Forte biosciences, inc. FBRX.US Overview
FBRX AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
FBRX Current Performance
-1.30%
Forte biosciences, inc.
0.98%
Avg of Sector
0.83%
S&P500
FBRX Key Information
FBRX Financial Forecast
Unit : USD
FBRX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -7.5 | - | -12.3% | 9K | - | -12.3% | - |
FBRX Profile
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Price of FBRX
FBRX FAQ
When is FBRX's latest earnings report released?
The most recent financial report for Forte biosciences, inc. (FBRX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FBRX’s short-term business performance and financial health. For the latest updates on FBRX’s earnings releases, visit this page regularly.
How much cash does FBRX have?
At the end of the period, Forte biosciences, inc. (FBRX) held Total Cash and Cash Equivalents of 45.86M, accounting for 0.97 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is FBRX's EPS continuing to grow?
According to the past four quarterly reports, Forte biosciences, inc. (FBRX)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.37. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of FBRX?
Forte biosciences, inc. (FBRX)’s Free Cash Flow (FCF) for the period is -10.42M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 56.09% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.